Abstract
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248 .
Keywords: AVIFAVIR; COVID-19; SARS-CoV-2; favipiravir.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Favipiravir, AVIFAVIR, 【초록키워드】 Treatment, clinical trial, Favipiravir, viral clearance, Registration, clinical, Patient, COVID-19 patients, AVIFAVIR, phase, Safe, treatment of COVID-19 patients, clearance, RNA polymerase inhibitor, Ministry of Health, SARS-CoV-2 viral, 【제목키워드】 clinical, phase, Result, Interim,
【저자키워드】 COVID-19, SARS-CoV-2, Favipiravir, AVIFAVIR, 【초록키워드】 Treatment, clinical trial, Favipiravir, viral clearance, Registration, clinical, Patient, COVID-19 patients, AVIFAVIR, phase, Safe, treatment of COVID-19 patients, clearance, RNA polymerase inhibitor, Ministry of Health, SARS-CoV-2 viral, 【제목키워드】 clinical, phase, Result, Interim,
{{{ 추상적인 }}}
2020년 5월 러시아 보건부는 COVID-19 환자 치료를 위해 RNA 중합효소 억제제 AVIFAVIR(파비피라비르)에 대한 신속 판매 승인을 승인했습니다. 2/3상 임상 시험의 파일럿 단계에서 AVIFAVIR은 4일 이내에 환자의 62.5%에서 SARS-CoV-2 바이러스 제거를 가능하게 했으며 안전하고 내약성이 우수했습니다. 임상 시험 등록. NCT04434248 .
{{ 키워드: }} AVIFAVIR; 코로나바이러스감염증-19 : 코로나19; 사스 코로나바이러스 2; 파비피라비르.